Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Michael Shinners

Otolaryngology Fargo, ND Medical Doctor

NPI 1447395512 CMS profile 110487

801 Broadway N, Fargo, ND 58102

Open in the dashboard

General payments

$7,820

35 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,825 paid to institutions, not to them · program years 2019–2020

Through program year 2024, Michael Shinners of Fargo, ND is reported in the CMS Open Payments database as having received $7,820 across 35 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,825 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $83 1
2023 General $170 2
2022 General $303 3
2021 General $266 6
2020 General $47 4
2019 General $6,950 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Shinners
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Michael Shinners were reported at $0. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Michael Shinners Otolaryngology median Middle half National median
2019 $6,950 $194 $82–$512 $163
2020 $47 $118 $42–$280 $114
2021 $266 $167 $63–$444 $132
2022 $303 $216 $84–$545 $149
2023 $170 $235 $93–$588 $160
2024 $83 $280 $111–$699 $164
2025 $0 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Cochlear Americas $7,142 23 payments
  2. Advanced Bionics, LLC $678 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $5,100 2 payments
  2. Travel and Lodging $1,454 8 payments
  3. Food and Beverage $1,266 25 payments
Products named General payments · program years 2019–2024
  1. Nucleus $6,781 17 payments
  2. Baha Implantable hearing solution $6,781 17 payments
  3. HIRES ULTRA CI HIFOCUS MS ELECTRODE Otolaryngology $386 4 payments
  4. Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode $361 6 payments
  5. HiResolution Bionic Ear System $217 6 payments
  6. Baha BI300 implant 4 mm $190 4 payments
  7. Cochlear Osia OSI200 Implant $190 4 payments
  8. BAHA Implantable hearing solution $170 2 payments
  9. OSIA OSI300 IMPLANT $170 2 payments
  10. HIRES ULTRA CI HIFOCUS MS ELECTRODE Otolaryngology $76 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

69

Median for Otolaryngology: 297

Drug cost

$2,681

Median for Otolaryngology: $6,314

Branded share of claims

65.2%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 13 $2,089
Ofloxacin Generic 24 $555
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 32 $38

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$30,654

Medicare's payments for the services billed

Medicare patients

108

Average age 72

Services billed

429

52 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 45%
Diabetes 31%
Ischemic heart disease 29%
Depression 23%
Chronic kidney disease 22%
Cancer 19%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

35 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record